Bristol Myers Squibb

BMY-N

NYSE:BMY

67.43
0.00 (0.00%)
Bristol-Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, ...
More at Wikipedia

Analysis and Opinions about BMY-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
January 22, 2020
A leading oncology drug producer, trading at 10x earnings and paying a 3% dividend. Many catalysts are coming. They merged with Celgene, a deal which has raised investor expectations, with potentially strong synergies. This could trade at 11x earnings. You can make 20% on this. Holding a healthcare name is key. (Analysts’ price target is $71.64)
Show full opinionHide full opinion
A leading oncology drug producer, trading at 10x earnings and paying a 3% dividend. Many catalysts are coming. They merged with Celgene, a deal which has raised investor expectations, with potentially strong synergies. This could trade at 11x earnings. You can make 20% on this. Holding a healthcare name is key. (Analysts’ price target is $71.64)
COMMENT
COMMENT
November 28, 2019
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
Show full opinionHide full opinion
BMY vs ABBV? Doesn't own either one of them at the moment. Both stocks will probably do just fine over the next couple of years. Bristol Myers acquisition of Celgene will give them new drug applications. Be cautious on the Canadian tax implication in this acquisition. AbbVie on the other end is struggling with drugs that have been in the pipeline for a number of years and will start to face generic competition. Well managed companies. More comfortable with Bristol Myers.
COMMENT
COMMENT
October 16, 2019

They're getting a good deal on Celgene. Can't say what he'll do with this stock, but BMY is attractive.

Show full opinionHide full opinion

They're getting a good deal on Celgene. Can't say what he'll do with this stock, but BMY is attractive.

DON'T BUY
DON'T BUY
October 4, 2019
It is a complex business with patents that come off, rising class-action lawsuits and rising regulatory threat politically in the US. He views it as a politically vulnerable industry and would suggest there are better things to buy. (Analysts’ price target is $59.00)
Show full opinionHide full opinion
It is a complex business with patents that come off, rising class-action lawsuits and rising regulatory threat politically in the US. He views it as a politically vulnerable industry and would suggest there are better things to buy. (Analysts’ price target is $59.00)
COMMENT
COMMENT
September 27, 2019

Bristol Myers's latest drugs haven't done as well as they thought. GSK has refocused into pharmaceuticals, and they sold off the consumer products division. After 5 years, they have both come to be around the same price. He would prefer GSK.

Show full opinionHide full opinion
Bristol Myers Squibb (BMY-N)
September 27, 2019

Bristol Myers's latest drugs haven't done as well as they thought. GSK has refocused into pharmaceuticals, and they sold off the consumer products division. After 5 years, they have both come to be around the same price. He would prefer GSK.

COMMENT
COMMENT
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

Show full opinionHide full opinion
Bristol Myers Squibb (BMY-N)
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

John Kim

Unlock Ratings

Price
$49.840
Owned
Unknown
DON'T BUY
DON'T BUY
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

Show full opinionHide full opinion

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

DON'T BUY
DON'T BUY
July 18, 2019
Acquisition pending, so some analysts aren't allowed to give an opinion while their investment bank is working on the deal. This is in the bucket of US healthcare he doesn't want to own right now. Political risk around drug pricing and lack of pipeline growth.
Show full opinionHide full opinion
Acquisition pending, so some analysts aren't allowed to give an opinion while their investment bank is working on the deal. This is in the bucket of US healthcare he doesn't want to own right now. Political risk around drug pricing and lack of pipeline growth.
COMMENT
COMMENT
July 17, 2019

BMY was going down before their Celgene purchase, which was a good deal (he owned Celgene) at a bargain. BMY didn't do anything particularly wrong; their drugs are doing well. However, Merck is the dominant player in this space with better science, and so is his preferred pick. Better to hold a basket of health stocks though to lessen risk in holding individual health stocks--science keeps changing.

Show full opinionHide full opinion

BMY was going down before their Celgene purchase, which was a good deal (he owned Celgene) at a bargain. BMY didn't do anything particularly wrong; their drugs are doing well. However, Merck is the dominant player in this space with better science, and so is his preferred pick. Better to hold a basket of health stocks though to lessen risk in holding individual health stocks--science keeps changing.

TOP PICK
TOP PICK
May 3, 2019
Has given up what Merck has gained. Likes the acquisition, and thinks the reaction is a bit overdone. Up almost 4% today, but still likes it. Yield is 3.37%. (Analysts’ price target is $58.00)
Show full opinionHide full opinion
Has given up what Merck has gained. Likes the acquisition, and thinks the reaction is a bit overdone. Up almost 4% today, but still likes it. Yield is 3.37%. (Analysts’ price target is $58.00)
DON'T BUY
DON'T BUY
April 22, 2019
Has one of the weakest pipeline among the big pharmas.
Show full opinionHide full opinion
Has one of the weakest pipeline among the big pharmas.
HOLD
HOLD
March 21, 2019
Some people don’t like the deal. CELG-Q and BMY-N like the deal. Stakeholders have come out against it. There is a lot of spread which represents the risk. Stay with it but understand the risks and don't have too big an exposure to it as there is deal risk.
Show full opinionHide full opinion
Some people don’t like the deal. CELG-Q and BMY-N like the deal. Stakeholders have come out against it. There is a lot of spread which represents the risk. Stay with it but understand the risks and don't have too big an exposure to it as there is deal risk.
HOLD
HOLD
December 17, 2018
He bought a put as this stock went down. Healthcare has been under pressure lately. Maybe have a January expiration. It's a sort of defensive stock, so okay to hold onto going into 2019.
Show full opinionHide full opinion
He bought a put as this stock went down. Healthcare has been under pressure lately. Maybe have a January expiration. It's a sort of defensive stock, so okay to hold onto going into 2019.
BUY
BUY
December 3, 2018
40% of their 2020 revenue is coming from Own diversity and own a few of these companies.
Show full opinionHide full opinion
40% of their 2020 revenue is coming from Own diversity and own a few of these companies.
TOP PICK
TOP PICK
November 22, 2018
They have a good, innovative pipeline. If you can get it in the low $50s, it will be a $60 stock next year. This is a good entry point. He likes it here below multiple multiples. (Analysts’ price target is $59.23)
Show full opinionHide full opinion
They have a good, innovative pipeline. If you can get it in the low $50s, it will be a $60 stock next year. This is a good entry point. He likes it here below multiple multiples. (Analysts’ price target is $59.23)
Showing 1 to 15 of 155 entries